Tyra Biosciences Inc (nasdaq:TYRA) Share Price

Company Profile

Business description
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company’s in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Contact
2656 State Street
CarlsbadCA92008
USA
T: +1 619 728-4760
https://www.tyra.bio
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
60

Recommended

A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.

Joseph Taylor | 16 July 2025

Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.

Brian Colello, CPA | 16 July 2025

These companies are our top choices for investors wanting to boost Aussie exposure.

Simonelle Mody | 15 July 2025

Index	Last price	Change	% Change
All Ordinaries	8,816.40	58.90	-0.66%
CAC 40	7,768.11	1.90	0.02%
DAX 40	24,091.25	30.96	0.13%
Dow JONES (US)	44,023.29	436.36	-0.98%
FTSE 100	8,954.56	16.24	0.18%
HKSE	24,517.76	72.36	-0.29%
NASDAQ	20,677.80	37.47	0.18%
Nikkei 225	39,663.40	14.62	-0.04%
NZX 50 Index	12,754.59	64.96	0.51%
S&P 500	6,243.76	24.80	-0.40%
S&P/ASX 200	8,561.80	68.50	-0.79%
SSE Composite Index	3,503.78	1.22	-0.03%